TY - JOUR
T1 - Decrease in IgE Fc receptor expression on mouse bone marrow-derived mast cells and inhibition of PAF-acether formation and of β-hexosaminidase release by dexamethasone
AU - Benhamou, M.
AU - Ninio, E.
AU - Salem, P.
AU - Hieblot, C.
AU - Bessou, G.
AU - Pitton, C.
AU - Liu, Fu-Tong
AU - Mencia-Huerta, J. M.
PY - 1986
Y1 - 1986
N2 - The effect of dexamethasone (DM) on the immunologic and nonimmunologic release of paf-acether and of the granule marker β-hexosaminidase (BHEX) from mouse bone marrow-derived mast cells (BMMC) was studied. BMMC (1 x 106) in a modified Tyrode's solution containing 0.25% bovine serum albumin (BSA) were sensitized with an optimal dose of dinitrophenyl (DNP)-specific monoclonal IgE, and were washed before challenge with 40 ng/ml of DNP coupled to BSA. Preincubation of BMMC for 24 hr with 1 nM to 1 μM DM inhibited in a dose-dependent fashion the immunologic release of paf-acether and of BHEX as compared with control cells, with a half-maximal effect at 20 nM and 4 nM respectively. By contrast, the ionophore A23187 (1 μM)-induced release of paf-acether and of BHEX was unaffected by DM pretreatment. Finally, the antigen-induced increase in acetyltransferase activity, used as an index of cellular activation, was inhibited by 37 ± 16% in 1 μM DM-treated BMMC as compared with untreated cells. Preincubation of BMMC with DM for 24 hr caused a dose-dependent inhibition of 125I-IgE binding to the cells, with a half-maximal effect at 14 nM. As determined by Scatchard analysis, the number of IgE Fc receptors was decreased by 55% in 1 μM DM-treated BMMC as compared with untreated cells, although the dissociation constants were comparable (control: 12.6 ± 4.1 nM; DM-treated cells: 14.1 ± 6.7 nM; mean ± SD; n = 3). Cytofluorometer analysis of BMMC sensitized with a saturating amount of purified monoclonal IgE, followed by addition of a fluoresceinated anti-mouse IgG (heavy and light chains), revealed a single cellular population for both DM-treated and untrated BMMC. This demonstrates that the DM-induced decrease in IgE Fc receptor expression was exhibited by every BMMC. The possible link between the decreased sensitization of the cells consequent to the reduction in IgE Fc receptor expression and the alteration of the secretory response and acetyltransferase activity was investigated. BMMC were incubated with IgE under experimental conditions giving half-sensitization of the cells. Upon antigen challenge, a 10.5 ± 3.7% decrease in acetyltransferase activity and a 29.2 ± 3.5% decrease in paf-acether release were observed with half-sensitized cells as compared with cells sensitized with a saturating amount of IgE. This result indicates that the decreased sensitization of the cells do not fully account for the inhibitions of paf-acether release and acetyltransferase activity observed upon DM treatment. These results indicate that DM inhibits the immunologic release of paf-acether and of BHEX from passively sensitized BMMC and decreases the IgE Fc receptor number available for sensitization. Thus, the modulation of IgE Fc receptor number could explain part of the anti-allergic properties of glucocorticosteroids.
AB - The effect of dexamethasone (DM) on the immunologic and nonimmunologic release of paf-acether and of the granule marker β-hexosaminidase (BHEX) from mouse bone marrow-derived mast cells (BMMC) was studied. BMMC (1 x 106) in a modified Tyrode's solution containing 0.25% bovine serum albumin (BSA) were sensitized with an optimal dose of dinitrophenyl (DNP)-specific monoclonal IgE, and were washed before challenge with 40 ng/ml of DNP coupled to BSA. Preincubation of BMMC for 24 hr with 1 nM to 1 μM DM inhibited in a dose-dependent fashion the immunologic release of paf-acether and of BHEX as compared with control cells, with a half-maximal effect at 20 nM and 4 nM respectively. By contrast, the ionophore A23187 (1 μM)-induced release of paf-acether and of BHEX was unaffected by DM pretreatment. Finally, the antigen-induced increase in acetyltransferase activity, used as an index of cellular activation, was inhibited by 37 ± 16% in 1 μM DM-treated BMMC as compared with untreated cells. Preincubation of BMMC with DM for 24 hr caused a dose-dependent inhibition of 125I-IgE binding to the cells, with a half-maximal effect at 14 nM. As determined by Scatchard analysis, the number of IgE Fc receptors was decreased by 55% in 1 μM DM-treated BMMC as compared with untreated cells, although the dissociation constants were comparable (control: 12.6 ± 4.1 nM; DM-treated cells: 14.1 ± 6.7 nM; mean ± SD; n = 3). Cytofluorometer analysis of BMMC sensitized with a saturating amount of purified monoclonal IgE, followed by addition of a fluoresceinated anti-mouse IgG (heavy and light chains), revealed a single cellular population for both DM-treated and untrated BMMC. This demonstrates that the DM-induced decrease in IgE Fc receptor expression was exhibited by every BMMC. The possible link between the decreased sensitization of the cells consequent to the reduction in IgE Fc receptor expression and the alteration of the secretory response and acetyltransferase activity was investigated. BMMC were incubated with IgE under experimental conditions giving half-sensitization of the cells. Upon antigen challenge, a 10.5 ± 3.7% decrease in acetyltransferase activity and a 29.2 ± 3.5% decrease in paf-acether release were observed with half-sensitized cells as compared with cells sensitized with a saturating amount of IgE. This result indicates that the decreased sensitization of the cells do not fully account for the inhibitions of paf-acether release and acetyltransferase activity observed upon DM treatment. These results indicate that DM inhibits the immunologic release of paf-acether and of BHEX from passively sensitized BMMC and decreases the IgE Fc receptor number available for sensitization. Thus, the modulation of IgE Fc receptor number could explain part of the anti-allergic properties of glucocorticosteroids.
UR - http://www.scopus.com/inward/record.url?scp=0022618739&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022618739&partnerID=8YFLogxK
M3 - Article
C2 - 2935578
AN - SCOPUS:0022618739
VL - 136
SP - 1385
EP - 1392
JO - Journal of Immunology
JF - Journal of Immunology
SN - 0022-1767
IS - 4
ER -